Dhuwit awis saben siji saham DiaMedica Corp (DMAC)

Lambang korporat lan logo DiaMedica Corp (DMAC)

DiaMedica Therapeutics (DMAC) is implementing advanced protein solutions to save organs from necrosis. The net cash position per share confirms the financial dynamics, where 0.65 indicates the current level. Capital is directed toward the activation of the kallikrein-kinin system for stroke therapy. Meanwhile, management is focused on clinical trials, the results of which will determine future shareholder confidence.

DMAC DiaMedica Corp: Dhuwit awis saben saham ing interval 04.07.2022 - 20.11.2026

Rincian metrik komprehensif lan analitis DiaMedica Therapeutics Inc (DMAC)

- rega lan prakiraan konsensus rega:
- rincian posisi dhuwit lan arus kas:
Ringkesan analisis perusahaan:DMAC, DiaMedica Therapeutics
Produk asil prodhuksi DiaMedica Therapeutics Inc.

For DiaMedica Therapeutics (DMAC), which is scaling clinical trials for drugs targeting renal pathologies, liquidity availability determines the ability to complete costly research without emergency borrowing. By analyzing the cash per share chart, an investor assesses the net cash balance divided by the number of shares, which allows for an evaluation of the issuer's financial autonomy and the level of capital protection against default.